Phase 3
N=127
Fetal and Infant Effects of Maternal Buprenorphine Treatment
Neonatal Abstinence Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT01561079 ↗Enrolled (actual)
127
Serious AEs
2.0%
Results posted
Aug 2017
Primary outcome: Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Buprenorphine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Johns Hopkins University
- Primary completion
- Jun 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fetal Heart Rate |
145.7; 143.3; 138.6; 136.3; 143.9; 141.0 | 0.001 sig |
| PRIMARY Fetal Heart Rate Variability |
5.4; 6.7; 7.5; 7.9; 4.9; 7.3 | <.002 sig |
| PRIMARY Accelerations of Fetal Heart Rate |
0.52; 1.59; 3.57; 5.28; 0.43; 2.12 | 0.0001 sig |
| PRIMARY Fetal Movement |
1496.2; 1390.0; 1458.7; 1446.7; 1613.0; 1385.7 | .008 sig |
| PRIMARY Fetal Movement - Fetal Heart Rate Coupling |
0.13; 0.21; 0.23; 0.25; 0.09; 0.20 | .002 sig |
Summary
This research will track the longitudinal neurobehavioral development of the buprenorphine-exposed fetus across gestation through 1 month of age in an effort to determine the safety of this medication for use during gestation, the relationship between maternal physiologic changes due to buprenorphine administration and newborn functioning, and to determine potential fetal neurobehavioral markers that may predict Neonatal Abstinence Syndrome expression and infant neurobehavioral outcome. Comparisons to results from a similar project in methadone-exposed pregnancies will be made. This proposal seeks to advance the way the investigators inform the treatment of the opioid dependent woman during pregnancy and her infant after birth.
Eligibility Criteria
Inclusion Criteria
- Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R criteria
- 18-40 years of age with uncomplicated singleton pregnancies
- Accurate gestational age dating verified by ultrasound
- Gestation of less than 34 weeks
- Stabilization on buprenorphine for one week prior to study procedures
Exclusion Criteria
- Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery (i.e. incompetent cervix)
- Evidence of fetal malformation detected by prenatal ultrasound
- Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension.
- Significant maternal psychopathology that would preclude informed consent (i.e. schizophrenia)
- Alcohol dependency per DSM IV R criteria (see ascertainment methods below)
- Women stable on methadone maintenance (defined as more than 3 days of methadone dosing)
- Women entering drug treatment reporting using "street" methadone (for more than 3 days)
Data sourced from ClinicalTrials.gov (NCT01561079). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.